Marit Sjo Lorentzen
Operationeel Directeur bij ARCTICZYMES TECHNOLOGIES ASA
Vermogen: 49 562 $ op 31-05-2024
Profiel
Marit Sjo Lorentzen is currently the Director at Biotec BetaGlucans AS and the Vice President-Operations at ArcticZymes Technologies ASA. She has an undergraduate degree from the University of Tromso.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
31-03-2023 | 20 331 ( 0.04% ) | 49 562 $ | 31-05-2024 |
Actieve functies van Marit Sjo Lorentzen
Bedrijven | Functie | Begin |
---|---|---|
ARCTICZYMES TECHNOLOGIES ASA | Operationeel Directeur | - |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Directeur/Bestuurslid | - |
Opleiding van Marit Sjo Lorentzen
University of Tromso | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |